Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergismsResearch in context

Summary: Background: Pharmacological synergisms are an attractive anticancer strategy. However, with more than 5000 approved-drugs and compounds in clinical development, identifying synergistic treatments represents a major challenge. Methods: High-throughput screening was combined with target deco...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Jérémy Ariey-Bonnet, Raphael Berges, Marie-Pierre Montero, Baptiste Mouysset, Patricia Piris, Kevin Muller, Guillaume Pinna, Tim W. Failes, Greg M. Arndt, Philippe Morando, Nathalie Baeza-Kallee, Carole Colin, Olivier Chinot, Diane Braguer, Xavier Morelli, Nicolas André, Manon Carré, Emeline Tabouret, Dominique Figarella-Branger, Marion Le Grand, Eddy Pasquier
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2023-09-01
Rangatū:	EBioMedicine
Ngā marau:	Drug combination screening Target deconvolution Pharmacological synergisms Glioblastoma Cancer vulnerabilities
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2352396423003171
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!